Abstract
In this study, we have analyzed the possibility of inducing T cell responses against small cell lung cancer (SCLC), a still incurable tumor, by cytokine gene transfer approaches. By RT-PCR analysis most SCLC expressed the CTL-defined tumor antigens MAGE-3 (10/11), MAGE-1 (7/11) and less frequently BAGE (4/11) and GAGE1,2 (4/11). Although the surface expression of HLA class I molecules was low on most SCLC, thus preventing CTL recognition, treatment of the cells with IFN-γ enhanced HLA-class I levels in all cases. Two MAGE3+ SCLC cell lines displaying the A2 HLA-class I allele, involved in MAGE-3 antigen presentation to CTL, were stably transfected with the IFN-γ gene (alone or co-transfected with IL-2). IFN-γ- transfected cells displayed a clearcut increase in expression of HLA-class I and β2 microglobulin at both protein and mRNA level, and of TAP-1 and TAP-2 mRNA. Perhaps more importantly, IFN-γ transfected cells were recognized by the MAGE-3-specific, A2-restricted antimelanoma CTL clone 297/22, while unmodified cells or cells transfected with the IL-2 gene alone were not. These data indicate that IFN-γ gene transfection into HLA-deficient SCLC cells is able to restore their ability to present endogenous tumor antigens to CTL and that IFN-γ gene transfer approaches may be attempted to induce specific CTL responses in SCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Traversari, C., Meazza, R., Coppolecchia, M. et al. IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther 4, 1029–1035 (1997). https://doi.org/10.1038/sj.gt.3300489
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300489
Keywords
This article is cited by
-
Signal pathways and precision therapy of small-cell lung cancer
Signal Transduction and Targeted Therapy (2022)
-
Small-cell lung cancer
Nature Reviews Disease Primers (2021)
-
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
Journal of Hematology & Oncology (2019)
-
IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells
Journal of Experimental & Clinical Cancer Research (2017)
-
Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer
Journal of Cancer Research and Clinical Oncology (2013)